STORY AT-A-GLANCE
- In 2019, Bill Gates invested $55 million in BioNtech, which developed the COVID-19 shot for Pfizer; it’s now worth $550 million
- Gates sold some of the stock at the end of 2022, when the share price was over $300
- After reaping huge profits, Gates criticized COVID-19 jabs, stating they don’t block infection, aren’t effective against variants and have “very short duration”
- Gates’ motivations run far deeper than making money off shrewd investments; by funding WHO, Gates is able to ensure that the decisions it makes end up profiting his own interests and those of his Big Pharma partners
- Gates, via collaborations with WHO, Anthony Fauci and others, is aiming to have absolute power to control pandemic declarations and responses worldwide
In The Hill video below, Bill Gates trashes mRNA COVID-19 shots, naming three problems with them that need to be fixed. “The current vaccines are not infection-blocking,” Gates says, “They’re not broad — so when new variants come up you lose protection — and they have very short duration, particularly in the people who matter, which are old people.”1
COVID-19 shots’ lack of efficacy and safety is not news, so why is this a remarkable statement coming from Gates? He’s been a major proponent of mRNA technology and invested heavily in BioNTech, which developed the COVID-19 shot for Pfizer. He’s since sold a lot of those shares, earning a 10x profit.
Gates Reaps Windfall Profits From mRNA Shot Investment
As reported by The Hill co-host Briahna Joy Gray, Gates invested $55 million in BioNtech in 2019, and it’s now worth